Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020

Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

(2022) Michael Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

(2021) Aino Rajamäki et al.   LEUKEMIA & LYMPHOMA

Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

(2021) David A Bond et al.   Blood Advances

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

(2021) Vincent Ribrag et al.   BLOOD

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

(2020) Dok Hyun Yoon et al.   Journal of Hematology & Oncology

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

(2020) Carlo Visco et al.   LEUKEMIA

Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis

(2020) Hongyu Wu et al.   Frontiers in Oncology

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

(2019) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma

(2019) Sumita Ratnasingam et al.   Scientific Reports

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial

(2019) Hanneke C. Kluin-Nelemans et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline for the management of mantle cell lymphoma

(2018) Pamela McKay et al.   BRITISH JOURNAL OF HAEMATOLOGY

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

(2016) Christian W. Eskelund et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

(2013) Dolores Caballero et al.   ANNALS OF HEMATOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

(2012) Christian H. Geisler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

(2012) Riikka Räty et al.   LEUKEMIA & LYMPHOMA

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

(2010) V. Fernandez et al.   CANCER RESEARCH

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD